Metastatic Non-Hodgkin's Lymphoma tumour model – SUDHL-6

SUDHL-6 cells

Human SYDHL-6 cells were isolated from the peritoneal effusion of a peritoneal NHL with mixed phenotype (large B-cells and follicular).

Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing SUDHL-6 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.



Figure 1: Tumour growth curve of the SUDHL-6 cells as xenograft Mean ± SEM (n=3; take rate 100%)

Antineo can also perform an intra-medullar implantation.

Standard-Of-Care Drug Reponses

CHOP, 30 mg/kg, once → Response



Figure 2: Effect of CHOP therapy on SUDHL-6 tumour growth Mean ± SEM (n=6 per group; take rate 100%)